The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient‐reported insights on symptoms and quality of life

OBJECTIVES: To assess the clinical, humanistic and economic burden of paroxysmal nocturnal haemoglobinuria (PNH) among C5 inhibitor (C5i)‐treated patients with PNH. METHODS: This was a web‐based, cross‐sectional survey (01FEB2021‐31MAR2021) of adults with PNH treated with eculizumab (France, Germany...

Descripción completa

Detalles Bibliográficos
Autores principales: Panse, Jens, Sicre de Fontbrune, Flore, Burmester, Pascale, Piggin, Maria, Matos, Joana E., Costantino, Halley, Wilson, Koo, Hakimi, Zalmai, Nazir, Jameel, Desgraz, Renaud, Fishman, Jesse, Persson, Emmelie, Kulasekararaj, Austin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545353/
https://www.ncbi.nlm.nih.gov/pubmed/35746830
http://dx.doi.org/10.1111/ejh.13816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545353/
https://www.ncbi.nlm.nih.gov/pubmed/35746830
http://dx.doi.org/10.1111/ejh.13816

Ejemplares similares